These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 17287904)

  • 1. A case of deep venous thrombosis associated with pegylated interferon alpha2b plus ribavirin treatment of chronic hepatitis C.
    Okuse C; Adachi K; Katakura Y; Matsunaga K; Ishii T; Matsumoto N; Yotsuyanagi H; Iino S; Suzuki M; Itoh F
    J Gastroenterol; 2006 Dec; 41(12):1231-6. PubMed ID: 17287904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
    Berenguer J; González-García J; López-Aldeguer J; Von-Wichmann MA; Quereda C; Hernando A; Sanz J; Tural C; Ortega E; Mallolas J; Santos I; Miralles P; Montes ML; Bellón JM; Esteban H;
    J Antimicrob Chemother; 2009 Jun; 63(6):1256-63. PubMed ID: 19363085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.
    Escudero A; Rodríguez F; Serra MA; Del Olmo JA; Montes F; Rodrigo JM
    J Gastroenterol Hepatol; 2008 Jun; 23(6):861-6. PubMed ID: 18422960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylated interferon-alpha 2b-ribavirin combination in Egyptian patients with genotype 4 chronic hepatitis.
    Derbala M; Amer A; Bener A; Lopez AC; Omar M; El Ghannam M
    J Viral Hepat; 2005 Jul; 12(4):380-5. PubMed ID: 15985008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection.
    Jara P; Hierro L; de la Vega A; Díaz C; Camarena C; Frauca E; Miños-Bartolo G; Díez-Dorado R; de Guevara CL; Larrauri J; Rueda M
    Pediatr Infect Dis J; 2008 Feb; 27(2):142-8. PubMed ID: 18174875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of early virological response to treatment with different interferon-based regimens plus ribavirin in patients with chronic hepatitis C.
    Napoli N; Giannelli G; Parisi CV; Antonaci A; Maddalena G; Antonaci S
    New Microbiol; 2005 Jan; 28(1):13-21. PubMed ID: 15782622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retreatment for 24 vs 48 weeks with interferon-alpha2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone.
    Enríquez J; Gallego A; Torras X; Pérez-Olmeda T; Diago M; Soriano V; Luján MS; García-Samaniego J
    J Viral Hepat; 2000 Nov; 7(6):403-8. PubMed ID: 11115050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
    El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
    Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interferon alfacon-1 and ribavirin versus interferon alpha-2b and ribavirin in the treatment of chronic hepatitis C.
    Sjogren MH; Sjogren R; Holtzmuller K; Winston B; Butterfield B; Drake S; Watts A; Howard R; Smith M
    Dig Dis Sci; 2005 Apr; 50(4):727-32. PubMed ID: 15844709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
    Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha2b plus ribavirin in HIV/HCV co-infected patients.
    Payan C; Pivert A; Morand P; Fafi-Kremer S; Carrat F; Pol S; Cacoub P; Perronne C; Lunel F;
    Gut; 2007 Aug; 56(8):1111-6. PubMed ID: 17363475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis.
    Roffi L; Colloredo G; Pioltelli P; Bellati G; Pozzpi M; Parravicini P; Bellia V; Del Poggio P; Fornaciari G; Ceriani R; Ramella G; Corradi C; Rossini A; Bruno S;
    Antivir Ther; 2008; 13(5):663-73. PubMed ID: 18771050
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2'-,5'-Oligoadenylate synthetase response ratio predicting virological response to PEG-interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C.
    Kim KI; Kim SR; Sasase N; Taniguchi M; Harada S; Kinoshita K; Kim SH; Akimoto Y; Shikata M; Kimura N; Izawa S; Ohtani A; Nakao K; Motojima M; Kinoshita M; Hirai M; Ohzu M; Hirooka T; Nabeshima S; Ishii F; Tanaka K; Hotta H
    J Clin Pharm Ther; 2006 Oct; 31(5):441-6. PubMed ID: 16958821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of pegylated interferon-alpha2a plus ribavirin versus pegylated interferon-alpha2b plus ribavirin in treatment-naive chronic hepatitis C patients.
    Lee S; Kim IH; Kim SH; Kim SW; Lee SO; Lee ST; Kim DG; Lee CS; Choi CS; Cho EY; Kim HC
    Intervirology; 2010; 53(3):146-53. PubMed ID: 20068348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
    Kim SR; Imoto S; Mita K; Taniguchi M; Sasase N; Muramatsu A; Kudo M; Kitai S; El-Shamy A; Hotta H; Hayashi Y
    Digestion; 2009; 79(1):36-9. PubMed ID: 19246919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum transaminase elevations during pegylated interferon treatment of chronic HCV hepatitis probably induced by polyethylene glycol.
    Caroleo B; Gallelli L; Staltari O; De Sarro G; Guadagnino V
    Intervirology; 2008; 51(6):407-9. PubMed ID: 19258719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced efficacy of pegylated interferon alpha-2a over pegylated interferon and ribavirin in chronic hepatitis C genotype 4A randomized trial and quality of life analysis.
    Kamal SM; Ahmed A; Mahmoud S; Nabegh L; El Gohary I; Obadan I; Hafez T; Ghoraba D; Aziz AA; Metaoei M
    Liver Int; 2011 Mar; 31(3):401-11. PubMed ID: 21281434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients.
    Santin M; Shaw E; Garcia MJ; Delejido A; de Castro ER; Rota R; Altés J; Baguena F; Valero S; Sala M; Casanova A;
    AIDS Res Hum Retroviruses; 2006 Apr; 22(4):315-20. PubMed ID: 16623633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
    Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
    J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safe use of pegylated interferon/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization.
    Foruny JR; Blázquez J; Moreno A; Bárcena R; Gil-Grande L; Quereda C; Pérez-Elías MJ; Moreno J; Sánchez J; Muriel A; Rodriguez-Sagrado MA; Moreno S
    Eur J Gastroenterol Hepatol; 2005 Nov; 17(11):1157-64. PubMed ID: 16215426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.